THOUSAND OAKS, Calif., Feb. 19 (HSMN NewsFeed) — Amgen Inc. (Nasdaq:AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company’s Complete Response submission for Prolia(TM) (denosumab) in the treatme…
Biopharmaceuticals, FDA
Amgen, Prolia, denosumab, osteoporosis

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date”
Leave a Comment